<div id="readability-page-1">We recently published a list of 10 Firms End Friday Strong; 3 Reach All-Time Highs. In this article, we are going to take a look at where Bristol-Myers Squibb Co. (NYSE:BMY) stands against other firms that end Friday strong.Wall Street’s main indices finished the trading week in the negative territory as investor sentiment was weighed down by economic uncertainties brought about by the ongoing trade tensions globally.The tech-heavy Nasdaq fell the heaviest, by 2.70 percent, followed by the S&amp;P 500, by 1.97 percent, and the Dow Jones, by 1.69 percent.Despite the broader market downturn, 10 individual stocks showed a strong performance during the trading session, with three companies particularly notable for hitting new all-time highs.In this article, we listed Friday’s top performers and detailed the reasons behind their gains.To come up with the list, we considered only the stocks with a $2-billion market capitalization and $5 million in trading volume.<div id="attachment_1196204"><img src="https://imageproxy.pbkrs.com/https://imonkey-blog.imgix.net/blog/wp-content/uploads/2023/09/21042610/BMY-insidermonkey-1695284767770.jpg/query-YXV0bz1mb3J0bWF0JmV4cGlyZXM9MTc3NDc0MjQwMCZmaXQ9Y2xpcCZoZWlnaHQ9MjY5JndpZHRoPTQ4MA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="830" height="465" original-src="https://imageproxy.pbkrs.com/https://imonkey-blog.imgix.net/blog/wp-content/uploads/2023/09/21042610/BMY-insidermonkey-1695284767770.jpg/query-YXV0bz1mb3J0bWF0JmV4cGlyZXM9MTc3NDc0MjQwMCZmaXQ9Y2xpcCZoZWlnaHQ9MjY5JndpZHRoPTQ4MA"/>A pharmacy shelves stocked with pharmaceutical drugs awaiting distribution.</div>Bristol-Myers saw its share prices increase by 1.90 percent on Friday to finish at $60.02 apiece following news that it earned the backing of a key European regulatory committee for its blockbuster cancer treatment Opdivo.According to BMY, the Committee for Medicinal Products for Human Use (CHMP), a part of the European Medicines Agency, recommended the approval of Opdivo for the treatment of adult solid tumors and is now being reviewed by the European Commission.A decision from the commission is expected to be released by June 2, 2025.In other news, BMY announced plans to acquire 2seventy Bio for $286 million. The transaction involved the purchase of all outstanding shares at a price of $5 apiece.The transaction is expected to be completed in the second quarter of the year, subject to customary closing conditions, including the tender of a majority of the outstanding shares of 2seventy Bio’s common stock and the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.Overall, BMY on our list of firms that end Friday strong. While we acknowledge the potential of BMY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is as promising as BMY but trades at less than 5 times its earnings, check out our report about the ..Disclosure: None. This article is originally published at Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal! The whispers are turning into roars. Artificial intelligence isn’t science fiction anymore. It’s the revolution reshaping every industry on the planet. From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards. Here’s why this is the prime moment to jump on the AI bandwagon: Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory. Imagine every sector, from healthcare to finance, infused with superhuman intelligence. We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything. This isn’t a maybe – it’s an inevitability. Early investors will be the ones positioned to ride the wave of this technological tsunami. Ground Floor Opportunity: Remember the early days of the internet? Those who saw the potential of tech giants back then are sitting pretty today. AI is at a similar inflection point. We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon. This is your chance to get in before the rockets take off! Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation. AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries. The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust. As an investor, you want to be on the side of the winners, and AI is the winning ticket. The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI. From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field. This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements. By investing in AI, you’re essentially backing the future. The future is powered by artificial intelligence, and the time to invest is NOW. Don’t be a spectator in this technological revolution. Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation. This isn’t just about making money – it’s about being part of the future. So, buckle up and get ready for the ride of your investment life! Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!) The AI revolution is upon us, and savvy investors stand to make a fortune. But with so many choices, how do you find the hidden gem – the company poised for explosive growth? That’s where our expertise comes in. We’ve got the answer, but there’s a twist… Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap. That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade! Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity. This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors. It’s like having a race car on a go-kart track. They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field. Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel. We want to make sure none of our valued readers miss out on this groundbreaking opportunity! That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 70%. For a ridiculously low price of just $29.99, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal! Here’s why this is a deal you can’t afford to pass up: • Access to our Detailed Report on this Game-Changing AI Stock:Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential. • 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan. • One free upcoming issue of our 70+ page Quarterly Newsletter:A value of $149 • Bonus Reports:Premium access to members-only fund manager video interviews • Ad-Free Browsing:Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity. • 30-Day Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked. Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment. Here’s what to do next: 1. Head over to our website and subscribe to our Premium Readership Newsletter for just $29.99. 2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months. 3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee. Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future! Subscribe Now! No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a year later! I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries. We’re independently funding today’s broadcast to address something on the mind of every investor in America right now… Should I put my money in Artificial Intelligence? Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin. Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance… But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down. That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet… And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day. He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance. Click to continue reading… </div>

TSVT

Bristol-Myers Squibb Co. (BMY) saw its share price rise by 1.90% to $60.02 on Friday, following positive news from the European regulatory committee regarding its cancer treatment Opdivo. The Committee for Medicinal Products for Human Use recommended approval for Opdivo for adult solid tumors, with a decision from the European Commission expected by June 2, 2025. Additionally, BMY announced plans to acquire 2seventy Bio for $286 million, with the transaction anticipated to close in the second quarter, pending regulatory conditions.

Why Bristol-Myers Squibb Co. (BMY) Went Up On Friday?